873055-15-3

Basic information

• Product Name: 1H-Indol-6-amine,3-ethyl-(9CI)
• Synonyms: 1H-Indol-6-amine,3-ethyl-(9CI)
• CAS NO: 873055-15-3
• Molecular Formula: C₁₀H₁₂N₂
• Molecular Weight: 160.219
• Product Categories: INDOLE
• Mol File: 873055-15-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1H-Indol-6-amine,3-ethyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Indol-6-amine,3-ethyl-(9CI)(873055-15-3)
• EPA Substance Registry System: 1H-Indol-6-amine,3-ethyl-(9CI)(873055-15-3)

Safety Data

• Hazardous Substances Data: 873055-15-3(Hazardous Substances Data)

Usage

Indole class

The compound belongs to the class of organic compounds called indoles, which are bicyclic aromatic compounds that contain a five-membered nitrogen-containing ring.

Derivative of indole

1H-Indol-6-amine,3-ethyl-(9CI) is a derivative of indole, which means it is a compound that has been modified from the structure of indole.

Indole ring structure

The compound contains an indole ring structure, which is a characteristic feature of indole compounds.

Ethyl group attached

The compound has an ethyl group (a two-carbon group) attached to the amine group at position 3 on the indole ring.

Physical appearance

The compound is a pale yellow to brown solid.

Melting point

The compound has a melting point of 80-85°C, which indicates the temperature range at which it changes from a solid to a liquid.

Uses

1H-Indol-6-amine,3-ethyl-(9CI) is used in the synthesis of pharmaceutical compounds and agrochemicals, and may have potential applications in the fields of medicine and agriculture.

Upstream product

• 74-96-4 ethyl bromide 
• 4769-96-4 6-nitroindole 
• 90915-25-6 3-ethyl-6-nitro-1H-indole 

Relevant articles and documents

5-SULFAMOYL-2-HYDROXYBENZAMIDE DERIVATIVES

The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to Formula (I): wherein R, R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof. The compounds of the invention are inhibitors of CD73 and can be useful in the treatment of cancer, pre-cancerous syndromes and diseases associated with CD73 inhibition, such as AIDS, the treatment of HIV, autoimmune diseases, infections, atherosclerosis, and ischemia–reperfusion injury. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting CD73 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Discovery of N -(2,4-Di- tert -butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a potent and orally bioavailable CFTR potentiator

Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screening in NIH-3T3 cells expressing the F508del-CFTR mutation. Extensive medicinal chemistry and iterative structure-activity relationship (SAR) studies to evaluate potency, selectivity, and pharmacokinetic properties resulted in the identification of N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for the treatment of CF patients 6 years of age and older carrying the G551D mutation.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.